Q-omics provides the consensus-scored LRRN4CL profile across patient tissues and cancer cell-line models. LRRN4CL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LRRN4CL is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, LRRN4CL RNA expression shows 21,270 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, BLCA, and BRCA as cancer lineages where LRRN4CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRN4CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRN4CL survival associations across molecular data types. LRRN4CL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRN4CL RNA expression–survival associations across cancer types. High LRRN4CL expression shows unfavorable associations in LGG, THCA, MESO and KIRC, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LRRN4CL RNA expression.
This table summarizes LRRN4CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRN4CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRN4CL shows lower tumor expression in BLCA, THCA, COAD, HNSC and LUSC and higher tumor expression in KIRC. The BLCA box plot shows higher LRRN4CL RNA expression in normal versus tumor tissue (log2 FC = −3.095, t-test p < 0.001).
This table shows molecular features associated with LRRN4CL in patient tissues and cancer cell lines. In patient samples, LRRN4CL shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRN4CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
